Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 13Cisplatin 9Capecitabine 7durvalumab 6pembrolizumab 4tremelimumab 3S 1 (combination) 3Nivolumab 3AZD 6244 3Ramucirumab 2Fluorouracil 2130-nm albumin-bound paclitaxel 2vandetanib 1trifluridine tipiracil drug combination 1trametinib 1tocilizumab 1titanium silicide 1sacituzumab govitecan 1poly ICLC 1futibatinib 1fludarabine 1cemiplimab 1binimetinib 1aflibercept 1Tegafur 1TAS-116 1Psilocybin 1Peptides 1Oxaliplatin 1NUC-1031 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Biliary Tract Neoplasms × TAS-116 × Clear all
NCT04999761 2024-09-25

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

Phase 1 Recruiting
917 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡